← All trials
NCT04622007
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 18, 2020
- Primary completion
- Mar 15, 2024
- Completion date
- May 31, 2024
- First posted
- Nov 9, 2020
- Last posted
- Nov 16, 2020
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Effector TherapeuticsLead sponsor
- Medpace, Inc.Collaborator
- Effector TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.